Catabasis Pharmaceuticals Inc.

Initiate a Phase 1b/2 clinical trial for QLS-215

Deadline passed; outcome being checked

Announced: 29 Jan 2021
Due: 31 Dec 2023
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“Catabasis expects to initiate a Phase 1b/2 trial in patients affected by HAE in 2023”

SourceCatabasis Pharmaceuticals Inc. Form 8-K press release, 2021-01-29
FilingSEC filing index
Deadline as statedin 2023
Deadline used31 Dec 2023, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-C454789-022640
Cite as https://keptindex.org/c/KI-C-2021-C454789-022640/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 1b/2 clinical trial
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High
Depends on: Regulatory

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Catabasis Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C454789-022640 · Corrections policy